Brand Name
Eraxis
Generic Name
Anidulafungin
View Brand Information FDA approval date: February 17, 2006
Classification: Echinocandin Antifungal
Form: Injection
What is Eraxis (Anidulafungin)?
ERAXIS is an echinocandin antifungal indicated for the treatment of the following infections: Candidemia and other forms of Candida infections in adults and pediatric patients .
Approved To Treat
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
Translational PKPD Modeling of Anti-infective Drugs in Children Treated in Pediatric Units on the Example of Selected Antibiotics and Antifungals.
Summary: Pharmacokinetic and pharmacodynamic modeling (PKPD) is becoming an essential tool for optimizing pharmacotherapy. Building mechanistic models allows determining the relationship between the dose, concentration, pharmacological effect, and side effects in various populations. The growing resistance to drugs among bacteria is a challenge for medicine, and the progress in pharmacometrics enables us t...
Impact of Capillary Leak and Hypoalbuminemia on PK/PD of Anidulafungin and Caspofungin in Critically Ill Patients
Summary: This prospective study will explore the pharmacokinetic exposure and pharmacodynamics of the echinocandins (caspofungin or anidulafungin) in critically ill patients.